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THE EFFECT OF SREBP ON GLUCOSE-INDUCED FAT ACCUMULATION IN 
INS-1 CELLS.  
PHANI DEEPTI JAKKILINKI 
 
The goal of this research project is to understand how a high sugar diet may affect 
pancreatic beta cell function. High glucose concentrations lead to an increase in lipid 
droplets and TORC1 in beta cells, which promote high basal secretion of insulin (Erion 
K.A. et al., JBC, 2015). SREBP is a key regulator of cholesterol and lipid synthesis and 
depends on TORC1 activity. The active form of SREBP is located in the nucleus.  
 
Does glucose-induced lipid synthesis in beta cells increase via SREBP? To answer this 
question, we propose: 1) To test the effect of high glucose (11mM) on nuclear SREBP in 
INS-1 cells in comparison to physiological glucose (4mM). 2) To determine if nuclear 
SREBP is affected when PIP4Kgamma (a regulator of TORC1) is suppressed.  
 
SREBP translocation from the cytosol to the nucleus was measured by 
immunofluorescence. SREBP processing was measured by western blot. SREBP1 
activation increased in response to prolonged exposure to excess glucose after at least 
48hrs. Both translocation and processing increased in 11mM glucose compared to 4mM 
glucose. When PIP4Kgamma was suppressed in INS-1 cells, SREBP translocation was 
inhibited. Lipid droplet accumulation was measured by nile red staining and it was found 
that de novo lipid synthesis only contributes to a small fraction of total lipid droplets. 
		 vii 
In conclusion, SREBP is activated in beta cells when in excess glucose. This may allow 
for lipid accumulation and basal hypersecretion of insulin due to over nutrition.   
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INTRODUCTION 
The impact of diet in obesity and diabetes  
According to the World Health Organization, 600 million people were obese in 
2014 and 422 million had diabetes (http://www.who.int/mediacentre/factsheets/fs311/en/; 
http://www.who.int/mediacentre/factsheets/fs312/en/). Obesity and diabetes are strongly 
associated and both are risk factors for cardiovascular diseases and other complications 
(Scappaticcio, Maiorino, Bellastella, Giugliano, & Esposito, 2016). One out of four 
annual deaths in the United States (US) is due to cardiovascular disease 
(https://www.cdc.gov/heartdisease/facts.htm). High calorie diets and low physical activity levels 
contribute to obesity and diabetes  
(http://www.who.int/genomics/public/geneticdiseases/en/index3.html). Due to the severity of these 
diseases, there is a strong need for multidisciplinary research to understand the 
physiological interplay between these two diseases. This study aims to better understand 
the role of pancreatic b cell dysfunction in diet-induced obesity and diabetes.  
 
Excess sugar consumption is a common component of a modern unhealthy diet. 
High carbohydrate diets may lead to hyperglycemia and excess fat accumulation, thereby 
increasing the risk of diabetes and obesity (Barazzoni et al., 2017). In an effort to 
understand the connection between obesity and diabetes in adults, one review 
summarized studies that evaluated the effects of low carbohydrate diets on obese subjects 
with type 2 diabetes. Overall, the results showed that subjects on a low carbohydrate diet 
lost weight and had enhanced insulin sensitivity, and lowered markers of diabetes such as 
	2 
hemoglobin A1C (HbA1c) levels. In addition, low carbohydrate diets lowered the need 
for type 2 diabetic medications (Matarese & Pories, 2014). Therefore, diet may be an 
important therapeutic target in treating obesity and diabetes in adults.  
 The prevalence of diabetes among American adolescents was 23% while the 
prevalence of obesity was 49% in 2008 (May, Kuklina, & Yoon, 2012). A review by 
O’Dowd and Stocker described evidence that diabetes risk begins at the embryonic 
developmental stage. This review described how a high fat diet during pregnancy 
negatively affected the development of the pancreas in both animal and human fetuses. 
The effects include low b cell number, poor b cell functioning, and hyperglycemia in the 
fetuses (O'Dowd & Stocker, 2013). Thus, a diet with excess nutrients negatively affects 
the pancreas and b cell functioning from fetal development to adulthood and thereby 
raises the risk of cardiometabolic diseases.  
 
This study explores how excess sugar may affect pancreatic b cell function, which 
may provide evidence for future Dietary Guidelines that avoidance of excess sugar could 
have beneficial long-term effects on health outcomes 
(https://health.gov/dietaryguidelines/2015/). It may also provide guidance for further research 
aimed at the development of medications that protect b cell function and reduce the risk 
of obesity and diabetes.  
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The role of b cells in regulating glucose homeostasis 
To understand how diet increases the risk of obesity and diabetes at the 
physiological level, one should understand how the pancreas is involved in the 
metabolism of sugar after a meal. The pancreas is an important organ that aids in 
digestion and metabolism. It consists of endocrine cells that secrete hormones and 
exocrine cells that produce enzymes for digestion (Frayn, 2013b). Pancreatic b cells are 
endocrine cells that produce insulin (Frayn, 2013b). There are also a cells that produce 
glucagon and d cells which produce somatostatin (Frayn, 2013a). This study will focus 
on b cells. Pancreatic b cells release insulin when there is an increase of glucose in the 
blood. Glucose is taken up by b cells through the GLUT2 transporter and metabolized 
through aerobic glycolysis to allow ATP production. This increase in ATP in the b cell 
closes potassium channels at the plasma membrane and leads to a change in membrane 
potential. Once the membrane is depolarized, calcium ions enter the b cell through 
voltage dependent calcium channels. This oscillation of calcium ions causes insulin to be 
released in a dose-responsive manner (Frayn, 2013b). Insulin allows the uptake and 
storage of glucose in various tissues and lowers it to normal levels in the blood (Frayn, 
2013b). In type 2 diabetes, glucose and insulin levels are not controlled properly and may 
result in hyperglycemia and insulin resistance.  
 
Bariatric surgery was recently found to be an effective method for improving or 
eliminating the presence of type 2 diabetes (Buchwald et al., 2009). One study of insulin 
sensitivity before and after Roux-en Y gastric bypass surgery among individuals with 
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type 2 diabetes found that b cell function (insulin secretion in response to glucose) and 
insulin sensitivity immediately improved after surgery (Gavin et al., 2014).  
 
Excess nutrients are stored in the body in the form of fat. Insulin allows the 
uptake of triacylglycerides from chylomicrons in the blood into the adipose tissue (Frayn, 
2013b). At the cellular level, insulin suppresses lipolysis and allows for the storage of 
lipids in adipose tissue (Chakrabarti et al., 2013). The liver also stores fat upon a meal. 
The presence of glucose and insulin in the blood will induce de novo lipogenesis in the 
liver. In the hepatocyte, glucose is converted to free fatty acids and stored as 
triglycerides. Thus, insulin is important for de novo lipogenesis, storage of triglycerides, 
and inhibition of lipolysis (Gong, Tas, Yakar, & Muzumdar, 2016).  
 
Studying the pancreatic b cell in excess nutrient conditions 
There are several studies that show that pancreatic b cells are affected by diet and 
disease conditions. For example, one study evaluated the changes in b cell mass and 
functioning in two groups of mice fed a high fat diet: high-responders and low-
responders to the high fat diet. The results showed that the mice that had a high weight 
gain had higher b cell mass as well as higher proliferation rate compared with mice who 
had less weight gain. The high-responders also had a high accumulation of cholesterol in 
their b cells (Peyot et al., 2010). A review stated that an accumulation of cholesterol 
inside b cells causes damage and decreases insulin secretion (Brunham, Kruit, Verchere, 
& Hayden, 2008). 
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Another study evaluated how hyperglycemia affects the pancreatic b cells of mice 
with neonatal diabetes and humans with type 2 diabetes. In the mice, hyperglycemia 
caused damage to b cell function and improper insulin secretion (in terms of insulin 
content) (Brereton et al., 2014). There are several aspects of b cell functioning under 
excess nutrient conditions that is still unknown such as how b cells metabolically adapt to 
excess nutrient conditions and how they fail to maintain adequate insulin secretion.  
 
Primary pancreatic b cells are difficult to use in research. For this reason, b cell 
lines were established in culture for research purposes. For example, INS-1 cells were 
cultured from the pancreases of rats that had been exposed to X- rays and had developed 
insulinomas. They allow scientists to explore how pancreatic b cells function under a 
controlled environment (Skelin, Rupnik, & Cencic, 2010). In this study, INS-1 cells have 
been used in the experiments. 
 
A study by Erion et al. showed that INS-1 cells have a high lipid accumulation 
when exposed to 11mM glucose compared with physiological 4mM glucose; they found 
a remarkable five-fold increase in fat accumulation (Erion, Berdan, Burritt, Corkey, & 
Deeney, 2015). There are two processes through which lipid accumulation occurs in 
cells. One is through the uptake of lipids from the environment that the cells are in and 
another is through the synthesis of lipids when needed by the cells. Depending on the 
requirements of cells, one process will be prioritized over the other to cope with the 
challenging environment. It is unknown whether increased lipid accumulation in INS-1 
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cells in the form of lipid droplets can be partially due to de novo lipid synthesis. This 
make this project novel.   
 
Molecular pathways for regulating lipid synthesis  
 TORC1 (target of rapamycin complex 1) is a kinase complex that signals for cell 
growth. The presence of glucose allows for the release of insulin that activates TORC1 
(Zoncu, Efeyan, & Sabatini, 2011). Glucose also activates TORC1 by increasing ATP. In 
the fed state (glucose conditions), the low AMP to ATP ratio inhibits AMPK which 
activates TORC1 (Weikel, Ruderman, & Cacicedo, 2016). TORC1 allows cell growth via 
lipid synthesis, protein translation, mitochondria biogenesis, and inhibition of autophagy 
(Zoncu et al., 2011). A study showed that TORC1 can regulate lipid synthesis through the 
activation of SREBP (Sterol Regulatory Element-Binding Protein) (Bengoechea-Alonso 
& Ericsson, 2007).  
 SREBP is one of the main transcription factors involved in cholesterol and lipid 
synthesis. SREBP1 activates genes for fatty acid synthesis and SREBP2 activates genes 
for cholesterol synthesis (Horton et al., 2003). In a cell, SREBP is located at the 
endoplasmic reticulum membrane (Diagram 1). This is the inactive cytosolic form of 
SREBP. In a sterol free environment, SREBP is transported to the Golgi apparatus and 
cleaved. Once cleaved it becomes activated, and is transported to the nucleus. This is 
called the active nuclear form of SREBP (Ikonen, 2008). This active nuclear SREBP will 
bind to the promoter called SRE (Sterol Responsive Element) to regulate the transcription 
of enzymes involved in cholesterol synthesis (Bengoechea-Alonso & Ericsson, 2007; 
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Ikonen, 2008). Active nuclear SREBP is short with a molecular weight of 60-70 kDa, 
whereas inactive cytosolic SREBP is longer with molecular weight of 125kDa 
(http://www.abcam.com/srebp1-antibody-2a4-ab3259.html). Most of the current research 
on SREBP is based on hepatocytes. In this study, we will investigate SREBP in the 
context of INS-1 cells, which makes this project unique. In future research, we will apply 
the knowledge gained to the study of pancreatic b cell function.  
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Diagram 1 – Model for SREBP activation in b cells: 1. INS-1 cells are exposed to high glucose concentration 
(11mM) and lipid free serum to activate SREBP. 2. SREBP (full length) is present in the endoplasmic reticulum. 
Upon activation, it is translocated to the Golgi apparatus destined for the nucleus. 3. SREBP is cleaved in the 
Golgi apparatus to generate a short active form. This can be measured by western blot. 4. The short active 
version of SREBP is further translocated to the nucleus, which can be measured by immunofluorescence. 5. The 
nuclear SREBP binds to the promoter of the genes for transcription of the enzymes for de novo lipid synthesis. 
This can be measured by qPCR. 6. The cells accumulate lipid droplets, which can be measured by nile red 
staining.  
 
There are several genes regulated by SREBP. In the process of triglyceride 
synthesis, SREBP1 is involved in regulating the transcription of three enzymes called 
ATP citrate lyase, acetyl-CoA carboxylase, and fatty acid synthetase. In the process of 
cholesterol synthesis, SREBP2 is involved in regulating the transcription of four enzymes 
called HMG-CoA synthetase, HMG-CoA reductase, farnesyl diphosphate synthetase, and 
squalene synthase. Depending on the conditions the cells are in, one process and the 
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transcription of the target enzymes are given preference (Horton, Goldstein, & Brown, 
2002). In this study, we will investigate the involvement of SREBP1 in lipid synthesis in 
INS-1 cells under high glucose conditions. 
 
Investigative questions of this project 
The main question addressed in this study is whether chronic exposure to high 
glucose activates SREBP in INS-1 cells (Diagram 2). Current evidence shows that 11mM 
glucose leads to increase in lipid droplets in INS-1 cells, which leads to high basal 
secretion of insulin and decreased glucose stimulated insulin secretion (Erion et al., 
2015). Therefore, understanding how high glucose promotes lipid accumulation will lead 
us to better understand how glucose causes b cell dysfunction. Preliminary data from the 
lab also showed that INS-1 cells chronically exposed to 11mM glucose had increased 
TORC1 activity as compared to INS-1 cells exposed to 4mM glucose (Zoncu et al., 
2011). As mentioned earlier, there is evidence that shows that higher TORC1 activity 
increased SREBP activation (Porstmann et al., 2008). TORC1 activity can be inhibited by 
kinase inhibitors such as KU006794 and genetic manipulations, such as PIP4Kg 
knockdown, which was shown to be a regulator of TORC1 (Mackey, Sarkes, Bettencourt, 
Asara, & Rameh, 2014).  
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Diagram 2 - Rationale and investigative questions: The rationale for this study is that it is known that high 
glucose concentration (11mM) increases lipid droplets in INS-1 cells and leads to a high basal secretion of 
insulin. Preliminary data from the Rameh lab show that high glucose increases TORC1 activity and other labs 
have shown that in liver cells, SREBP activation was TORC1 dependent. In this study, we have three 
investigative questions (indicated by “?”). 1) To test the effect of chronic exposure to high glucose (11mM) on 
SREBP activation in INS-1 cells compared with physiological glucose (4mM).; 2) To determine if TORC1 
inhibition blocks the activation of SREBP in INS-1 cells exposed to 11mM glucose. 3) To determine if SREBP 
activation is affected when PIP4Kg is suppressed. 
 
There are three main investigative goals of this project: 1) to test the effect of 
chronic exposure to high glucose (11mM) on active nuclear SREBP in INS-1 cells 
compared with physiological glucose (4mM); 2) to determine if KU006794, a TORC1 
inhibitor, blocks the translocation of SREBP into the nucleus in INS-1 cells exposed to 
11mM glucose; and 3) to determine if nuclear SREBP is affected when PIP4Kg is 
suppressed. While conducting the experiments to answer these investigative questions, an 
additional experiment was required which involved assessing the growth rates of 
different INS-1 cell lines in 4mM and 11mM glucose.  
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The hypotheses are as follows: 1) nuclear SREBP activity will increase when 
INS-1 cells are exposed to 11mM glucose in comparison to 4mM glucose; 2) KU006794 
will inhibit TORC1 activity, and therefore SREBP processing and/or translocation into 
the nucleus will decrease or be inhibited; 3) PIP4Kg knockdown cells will have a 
decreased SREBP activation.    
The experiments investigate the possible correlation between high glucose leading 
to an increase in TORC1 processing, and subsequently an increase in SREBP 
translocation to the nucleus. The results can establish that SREBP may be involved in this 
process of lipid droplet synthesis in INS-1 cells. In addition, the results can show how the 
formation of lipid droplets may depend on TORC1 activity under high glucose 
conditions. 
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METHODS 
Cells 
For all experiments, INS-1 cells have been used. These cells were infected with 
pSuper viruses, which allow for expression of short hairpin RNA (shRNA) to target 
specific transcripts for degradation (Mackey et al., 2014). The pS-C1 cells express a 
control shRNA and pS-IIγ express a shRNA for PIP4Kg knockdown. The pS-IIb cells 
express a shRNA for PIP4Kb knockdown. Infected cells expressing the pSuper virus 
were selected by puromycin treatment and knockdown was confirmed by western blot 
(Figure 1). INS-1 cells were maintained in 4mM glucose RPMI with 10% FBS, 
supplemented with 9mM Hepes buffer, 0.9mM sodium pyruvate, and 55µM b-
Mercaptoenthanol. This was the basic media used in all of the experiments. The cells 
were cultured at 37°C in a humidified CO2 incubation. The media was changed every 2-3 
days. The cultures were passaged every three days. 		
Immunofluorescence 
First, coverslips were sterilized with ethanol and flamed using a bunsen burner. 
They were then coated with 0.02mg/mL polylysine for at least one hour. The coverslips 
were washed three times with sterile water. INS-1 cells were trypsinized and counted 
with a hemocytometer. Based on the cell count, INS-1 cells were plated at the appropriate 
number to achieve the desired cell density at the end of the experiment. The cells were 
plated in media containing 4mM glucose. KU006794 (0.05µM or 0.4µM by Chemdea) 
and glucose (final 11mM) were added to appropriate conditions every 24 hours. 24hrs 
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before fixing cells, the media was changed to RPMI with 10% FBLPDS (fetal bovine 
lipoprotein deficient serum by Intracel) and the appropriate glucose concentration. 2-
4hours before fixation, ALLN (0.05mM by Sigma) was added to prevent the degradation 
of nuclear SREBP1. Cells were fixed with 4% paraformaldehyde for 10 mins. The 
coverslips were washed with 1X PBS three times and cells were permeabilized with 0.2% 
triton in PBS for 5mins. After washing three times with 1X PBS, the cells were blocked 
with 10% donkey serum in 1X PBS at room temperature. After 1 hour, the cells were 
incubated with primary antibody (mouse anti-SREBP-1 by BD bioscience and rabbit anti 
phospho-S6 ribosomal protein antibody by Cell Signaling Technologies) overnight. The 
next day, cells were washed three times with 1X PBS. The cells were incubated with 
secondary antibody (donkey anti-rabbit CY2 by Jackson Immunoresearch, and goat anti-
mouse CY3 by Jackson Immunoresearch) and dapi for one hour. After 1 hour, the 
coverslips were washed three times with 1X PBS and mounted with Fluoromount-G 
mounting solution on slides. Images were captured with Leica SP5 confocal microscope 
and quantified with Image J software.  
 
Growth Curve of INS-1 Cells 
INS-1 cells were trypsinized and counted with a hemocytometer. The pS-C1, pS-
IIγ, or pS-IIb cells were used in these experiments. For the growth curve in 4mM glucose 
media, a total of 4 million cells of each cell line were plated in 35mm plates, 36 in total. 
For the growth curve in 11mM glucose media, a total of 2 million cells of each cell line 
were plated. Each day, two plates (serving as duplicates of each cell line under each 
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condition) were trypsinized and counted with a hemocytometer for a total of 10-11 days. 
The final volumes of trypsin and media were adjusted based on the cell growth. These 
volumes were noted and used to calculate the total cell number for each day data point. 
The total cell count per plate was used for plotting the growth curves of these cells in 
4mM or 11mM glucose over time.  
 
Western Blot 
INS-1 cells were pre-cultured in 4mM or 11mM glucose media. After 24hrs, they 
were plated in a 12 well dish and exposed to 4mM or 11mM glucose for various times. 
0.05µM KU006794 was added to a set of pS-C1 and pS-IIγ cells at these various times. 
24hrs before lysing the cells, the media was changed to RPMI with 10% FBLPDS. Two 
hours before lysis, ALLN (0.05mM) was added to cells. 30 mins before lysis, MG132 
(5µM by Sigma) was added to all cells. The cells were lysed with sample lysis buffer 
with ALLN (0.05mM). After five minutes on ice, the lysed samples were collected into 
an eppendorf tube. The tubes were placed on a shaker for 30mins at 75°C to break 
chromosomic DNA and at 100°C for five minutes to denature the proteins. The protein 
lysates were run on a 10% SDS PAGE. They were transferred on to a nitrocellulose 
membrane. The membrane was then blocked with TBS 5% non-fat milk and incubated 
with purified mouse Anti-SREBP-1 antibody and rabbit pan-actin antibody (by Cell 
Signaling Technology) overnight at 4°C. The next day, the membrane was incubated with 
goat anti-rabbit 680 (by Molecular Probes) and goat anti-mouse 800 (by Li-Cor), which 
are secondary antibodies that fluoresce in the infrared.  The membrane was washed in 
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TBST three times and scanned using the Odyssey LiCor. The short and long SREBP1 
bands were quantified. The short SREBP is 60-70 kDa, while the long SREBP is 120kDa 
(http://www.abcam.com/srebp1-antibody-2a4-ab3259.html).    
 
Lipid Staining 
INS-1 cells were pre-cultured in 4mM or 11mM glucose media. After 48hrs, they 
were plated on glass coverslips coated with polylysine and cultured in 4mM or 11mM 
glucose for an additional 48hrs. KU006794 (0.05µM) was added to a set of pS-C1 and 
pS-IIγ cells. 24hrs before fixation, the media was changed to RPMI with 10% FBLPDS. 
As a positive control condition, a set of cells were kept in RPMI with 10% FBS that 
contains lipids. The next day, the cells were stained with nile red (1mg/1mL) for 30mins 
and fixed with 4% para-formaldehyde. After 20mins, the coverslips were washed with 1X 
PBS three times. The coverslips were mounted with Fluoromount-G mounting solution 
on slides. Images were taken with Leica SP5 confocal microscope and quantified with 
Image J software.  	
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RESULTS 
In the series of experiments presented in this study, INS-1 cells were challenged 
with 4mM and 11mM glucose to assess how physiological and excess glucose affect b 
cell lipid metabolism. 4mM glucose is considered as physiological glucose at fasting 
state. This is the glucose concentration that is maintained in the body and allows for 
proper b cell function. After a meal with excess carbohydrates, blood glucose levels can 
reach 11mM temporarily which is considered as high levels of glucose.  
 
Lipid droplets form in INS-1 cells under high glucose conditions (Erion et al., 
2015). This is a process by which cells store excess lipids formed due to excess nutrients. 
Improper lipid metabolism causes pancreatic b cell dysfunction. In this project, we are 
investigating how excess glucose results in lipid accumulation in b cells. More 
specifically, we are investigating whether SREBP1 plays an important role in de novo 
lipid synthesis in INS-1 cells through TORC1 activation.  
 
SREBP is an unstable transcription factor that is prone to degradation 
(Bengoechea-Alonso & Ericsson, 2016). Due to this reason, it is difficult to precisely 
quantify the cytosolic inactive SREBP and nuclear active SREBP levels in cells. In order 
to tackle this issue, we are conducting three different types of experiments to investigate 
SREBP1 activation in INS-1 cells exposed to physiological (4mM) or excess (11mM) 
glucose (Diagram 1). The physiological glucose means basal levels of glucose as fuel. 
The excess glucose means excess fuel, which can be both post prandial or pathological 
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type 2 diabetes level of glucose in the blood. The excess levels of glucose is not good for 
the cells. The three methods are the following: 1) Immunofluorescence: this method 
allows the subcellular localization of SREBP1 in fixed cells. Quantifying the nuclear and 
cytosolic SREBP1 gives information on the translocation of SREBP1 to the nucleus and 
therefore its activation state; 2) Western blot: this method allows quantifying the amount 
of the short versus long SREBP1 to provide a ratio. A high ratio (short: long) implies 
increased SREBP1 activation; 3) qPCR: this method quantifies the expression levels of 
SREBP gene targets. In addition, we also measured nile red staining, which allows for 
quantifying the amount of lipid droplets in cells.  
 
In all of the experiments mentioned above, we used INS-1 cells infected with 
pSuper-derived retrovirus (pS) (Mackey et al., 2014). The pS-C1 cells are the control 
cells. The pS-IIg cells have the PIP4Kg isoform knockdown, while the pS-IIb cells have 
the PIP4Kb isoform knockdown. The environment in which the INS-1 cells are in is 
important to the experimental design: 1) RPMI media with 4mM glucose (physiological) 
supplemented with 10% FBS (with or without lipids), Sodium Pyruvate (1mM) and 
Hepes buffer (10mM); 2) RPMI media with 11mM glucose (excess) supplemented with 
10% FBS (with or without lipids), Sodium Pyruvate (1mM) and Hepes buffer (10mM). 
For the following results, media 1 is referred to as 4G and media 2 is referred to as 11G. 
Table 1 shows the different experimental groups used.  
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Table 1: Experimental groups 
INS-1 Cell 
line 
Glucose 
treatment 
Time of 
exposure 
(hrs) 
KU006794 
treatment 
Experimental 
techniques 
pS-C1 4G  -/+ Immunofluorescence 
Western blot 
Nile red staining 
qPCR 
Growth curve 
 
 
 
11G 
 
 
24, 48, 72, 96 
 
 
-/+ 
pS-IIg 4G  - Immunofluorescence 
Western blot 
Nile red staining 
qPCR 
Growth curve 
11G 24, 48, 72, 96 - 
*Note: The pS-IIb cells were used in the growth curve of 4mM glucose as shown in 
Figure 1.  
 
The effect of glucose on INS-1 proliferation  
To successfully compare SREBP1 activity and lipid accumulation in cells in all of 
the experimental groups, cell density is crucial. If the final number of cells in each 
condition is different, the conclusions could be compromised, because there would be 
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two variables. To be able to calculate the exact number of cells to plate for each condition 
in order to achieve the equal number of cells at the end of the experiment, we conducted 
growth curves of INS-1 cells. Through these curves, we can calculate the doubling time 
which is the time that takes for the population to double (cell number). All three lines of 
INS-1 cells, pS-C1, pS-IIg, and pS-IIb were grown in 4mM (Figure 1 A and B) or 11mM 
glucose (Figure 2 A and B) and the data was plotted in a regular (Figure 1A and 2A) or 
log scale (Figure 1B and 2B). Although there was fluctuation from point to point, which 
can be due to error in the initial plating, the doubling time for pS-C1 cells was calculated 
to be approximately 50hrs. There was no large difference in doubling time between the 
cell lines, so these cells have a similar growth pattern in 4mM glucose. Therefore, the 
knockdown of PIP4Kg and PIP4Kb did not have a major effect on the proliferation rate 
of the cells in 4mM glucose. 
 
As seen in Figure 2, in 11mM glucose, the INS-1 cells appeared to have an 
exponential growth phase in the beginning and experienced cell death after 130hrs in 
culture. The doubling time for pS-C1 cells and pS-IIg cells was 20hrs. Therefore, the cells 
grew at a 2.5-fold faster rate in 11mM glucose than in 4mM glucose. The results show 
that PIP4Kg knocked down did not affect cell growth in 11mM (Figure 2 B). 
 
The effect of glucose and TORC1 activation on subcellular localization of SREBP1 
We used immunofluorescence to measure nuclear SREBP1 as a way to determine 
the SREBP1 activation state. In this experiment, pS-C1 and pS-IIg cells growing in 4mM 
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glucose (control condition) were exposed to 11mM glucose for 24hrs, 48hrs, and 72hrs. 
The main challenge of this experiment was achieving similar cell density for all 
conditions. The doubling times from the growth curves allowed us to properly calculate 
the number of cells to plate for each condition. The KU006794 inhibitor was added to a 
set of pS-C1 cells during the time of exposure to 11mM glucose. After 72hrs, the cells 
were fixed, stained using the immunofluorescence techniques, and imaged under a 
confocal microscope. SREBP1 was stained to visualize its location within the nucleus 
and in the cytosol. Dapi was used to stain and define the nucleus for quantification 
purposes. Phospho-S-6 was also stained as it is activated by TORC1. It serves as a 
control to confirm TORC1 activation and shows if the KU006794 inhibitor worked. The 
images were quantified using Image J software. For all conditions, the mean intensity 
value of the pixels for the SREBP1 staining inside the nucleus (within Dapi) and outside 
the nucleus (outside the Dapi) were quantified. The values were calculated as the 
following: 1) SREBP/Dapi and 2) SREBP nuclear/SREBP total.   	
Figures 3-4 show the images of this experiment. SREBP is stained in red, 
phospho-S-6 in green, and the nucleus in blue. When SREBP is in the nucleus, the 
combined images will show a purple staining due to the blue dapi staining, as seen in 3C. 
On the other hand, when SREBP is not in the nucleus, the combined image shows a 
predominantly blue staining in the nucleus, as seen in 3A. When SREBP is in the cytosol, 
we should see a red staining outside of the nucleus, and the combined image with 
phospho-S-6 will look yellow, as seen in 3F. For images in each channel separately, 
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please refer to the appendix (Figure 19-20). For the high magnification images for 
Figures 3 and 4, please refer to the appendix (Figure 17-18). We also show the gray scale 
images of the SREBP staining in Figure 19-22 and phospho-S-6 staining in Figure 23 and 
24 after separation of each channel for better appreciation of the distribution of SREBP 
and intensity of pS6 (see appendix).  
 
For the cells grown in 4G, there is little SREBP staining inside the nucleus of the 
cells, and more SREBP staining outside of the nucleus, which means that nuclear 
SREBP1 is low and therefore most of the SREBP1 is inactivated (Figure 3 A and 
appendix). The pS-C1 11G 24hrs panel shows that phospho-S-6 increased, which means 
that TORC1 has been activated after 24hrs of glucose exposure (Figure 3 B and 
appendix). However, SREBP1 did not change after 24hrs 11G, as compared to the control 
4G. In pS-C1 11G 48hrs panel, there was significantly more red staining inside the 
nucleus, which created a purple stain, indicating glucose induced SREBP1 activation 
(Figure 3 C and appendix). In pS-C1 11G 72hrs panel, there was even greater SREBP1 
staining inside the nucleus in comparison to 11G 48hrs which can be seen as brighter 
purple in the combined stained image (Figure 3 E and appendix). This implies that 
SREBP1 was activated over time of exposure to excess glucose and this activation was 
delayed in comparison to TORC1.  
 
A total of three images were captured per condition using the confocal 
microscope, containing approximately 50-100 cells per field. All three images were 
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quantified using Image J software. After quantification of dapi, nuclear and cytosolic 
SREBP1 staining, the ratio of nuclear SREBP/dapi and nuclear SREBP/total SREBP 
were calculated and corresponding graphs were generated (Figure 5 and 6). The graphs 
confirmed that nuclear SREBP increased gradually with glucose exposure and was 
highest at 72hrs.  
 
In the pS-C1 11G 48hrs + KU006794 condition, we observed that there was less 
number of cells/field (Figure 3 D). Thus, KU006794 (TORC1 inhibitor) seems to have 
caused some cell death in this condition. In the pS-C1 11G 72hrs + KU006794 condition 
(Figure 3 F), there was less SREBP staining inside the nucleus (less purple in the 
combined images)  in comparison to the pS-C1 11G 72hrs –KU (Figure 3 E). This means 
that KU006794 inhibited glucose-stimulated SREBP1 activation or translocation to the 
nucleus. The plotted quantification confirmed KU006794 decreased the SREBP/Dapi 
ratio in the 11mM 72hrs condition, but not in the 11mM 48hrs condition (Figure 5 A). 
Similar results were obtained when the ratio between the nuclear SREBP and total 
SREBP was calculated (Figure 5 B).  
 
In the pS-IIg cells, nuclear SREBP is slightly higher than control even in 4mM 
glucose (Figure 4). Interestingly, we also observed that pS-IIg cells have less phospho-S6, 
as previously reported (Mackey et al., 2014). This is seen when we compare panel 4C 
with 4D. In the pS-IIg cells treated with 11G for 24hrs and 48hrs, there is less SREBP 
staining inside the nucleus (less purple stain in the combined image) in comparison to 4G 
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and pS-C1 cells (Figure 4). This is confirmed by the quantification of nuclear 
SREBP/Dapi and nuclear SREBP/total ratios (Figure 6 A and 6 B). It can be said that 
knocking down PIP4Kg decreases SREBP translocation to the nucleus. Therefore, 
nuclear SREBP increased after prolonged exposure to 11mM glucose over the time 
course of 72hrs in pS-C1 cells but not in pS-IIg.  
In a second immunofluorescence experiment, we confirmed that at 72hrs, 
KU006794 treatment decreased nuclear SREBP (Figure 7 B and 25 B appendix). PIP4Kg 
knockdown decreased nuclear SREBP as there is more red SREBP staining outside of the 
nucleus (Figure 7 C and 25 C). The results indicate that the total protein levels of 
SREBP1 seem to increase with glucose but it is important to note that we did not use a 
proteasome inhibitor such as MG132 in the immunofluorescence experiments. 
 
The effect of glucose and TORC1 on SREBP1 cleavage 
In this experiment, pS-C1 and pS-IIg cells growing in 4mM glucose (control 
condition) were exposed to 11mM glucose over a period of 24hrs, 48hrs, or 72hrs. The 
KU006794 inhibitor was added to a set of pS-C1 cells during exposure to 11mM glucose. 
Before collecting the lysates, ALLN and MG132 were added to the cells. ALLN is a 
calpain inhibitor (https://www.gbiosciences.com/ALLN). MG132 is a proteasome 
inhibitor  (http://www.selleckchem.com/products/MG132.html). ALLN was previously 
shown to protect the short SREBP version, while MG132 was shown to protect the long 
SREBP version. These inhibitors were used to keep the short and long forms of SREBP 
stable before cells were lysed. After following the gel electrophoresis and western blot 
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techniques (Figure 8 A), the short and long SREBP1 bands were quantified and the ratio 
was calculated. Figure 8 B and C are the quantification of Figure 8 A, and Figure 8 D and 
E are the quantification of a separate western blot result with the same lysates from 
Figure 8A. The result shows that in pS-C1 cells the short/long SREBP1 ratio gradually 
increased overtime of exposure to 11G in comparison to 4G (Figure 8). The ratio in the 
11G 48hrs condition was significantly higher than the other however this could be due to 
an artifact in the quantification of the blot in Figure 8 A since in Figure 8D and E the 
bands were significantly lower. The addition of KU006794 decreased the ratio but only in 
the 24hrs exposure time (Figure 8 B). For the pS-IIg cells, the ratio of short/long was 
similar to pS-C1 cells (Figure 8 C and E).  
 
Figure 9 A shows the western blot for the second experiment where we repeated 
the experiment shown in Figure 8 but we exposed the INS-1 cells to 11mM glucose over 
a period of 48hrs, 72hrs, or 96hrs. We also blotted for phospho-S6 and total S6 to 
measure TORC1 activity, and actin as a loading control. The ratio of pS6/Total S6 
increased overtime in 11G in comparison to 4G in pS-C1 cells, which indicates that 
TORC1 was activated by excess nutrients in this experiment (Figure 10 B). Although 
KU006794 was expected to inhibit TORC1 activity, we observed that the pS6/total S6 
ratio showed that TORC1 was not completely inhibited in the KU006794 treated pS-C1 
cells. In fact, in the 11G 72hrs condition, it seems that KU006794 increased TORC1 
activity but we assume it was due to an artifact because that lane had little protein (Figure 
10 B). We see that there is more long SREBP than short SREBP. The total levels of 
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SREBP1 fluctuated during the course of the experiment, where it was higher in 11G 
48hrs and decreased in 11G 96hrs (Figure 10 C). Comparing Figure 8 and Figure 9, we 
can say that there is a lot more long SREBP on the second experiment. The ratio of 
short/long SREBP increased over time in 11G in comparison to 4G in pS-C1 cells (Figure 
10 A). In the cells treated with KU006794, we also saw an increase in the short/long 
SREBP ratio in response to excess glucose over time. Both short SREBP and long 
SREBP bands were normalized by total S6 which was used as a loading control since 
actin bands were faulty (Figure 10 C and D). Therefore, SREBP1 seems to be activated in 
response to excess glucose confirming the immunofluorescence experiments. 
Unfortunately, we cannot make conclusions regarding TORC1 role in SREBP1 activation 
because KU006794 did not fully inhibit TORC1 after 24hrs of treatment.  
 
The pS6/Total S6 ratio in pS-IIg cells increased overtime and peaked over 72hrs 
of exposure to 11G (Figure 11 B). We expected knock down of PIP4Kg would decrease 
TORC1 in the early time points but not in the later time points.  In the 11G 96hrs, there 
was a slight decrease of TORC1 activity in pS-IIg cells as compared to the control. The 
ratio of short/long SREBP increased in pS-IIg cells over time of exposure to 11G in 
comparison to 4G and it was similar to pS-C1 cells except in 4G (Figure 11 A). Thus, pS-
IIg does not seem to affect processing of SREBP1 under excess nutrients.  
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The effect of glucose on lipid accumulation in INS-1 cells 
In this experiment, we investigated if lipid droplet accumulation in INS-1 cells 
under excess glucose conditions is due to TORC1 activity. The pS-C1 and pS-IIg cells 
growing in 4mM glucose (control condition, 4G) were exposed to excess glucose (11G) 
over a period of 96hrs. The KU006794 inhibitor was added to a set of pS-C1 cells during 
exposure to 11mM glucose. After 72hrs, 24hrs hours before fixing the cells, one set of 
11G cells and the 4G cells were changed to lipid free serum. One set of 11G cells were 
kept in serum with lipids, as a positive control. After 96hrs of exposure to excess glucose, 
all cells were stained with nile red and fixed. Nile red stains for lipid droplets. The cells 
were imaged with a confocal microscope, using the green channel (excitation 488nm, 
emission 500-560) as seen in Figure 12-13 and the red channel (excitation 543nm, 
emission 570-620) as seen in Figure 15-16. Nile red fluoresces on red therefore, red 
channel detects polar lipids in the cells. Nile red will shift to the green channel when its 
bound to cholesterol and triglycerides. Therefore, the green channel detects neutral lipids 
inside the cell (Greenspan & Fowler, 1985). Figure 15 shows that nile red emission in the 
red channel stains more than just lipid droplets. We used Image J software to eliminate 
the background of the cell membrane and quantify the integral density of pixels of the 
lipid droplets. We normalized according to cell number per image (three images per 
condition with 300-400 cells per image). The errors bars in the quantifications are large 
showing variability within different fields, which may compromise the accuracy of the 
experiment.  
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The quantification of Figure 14 A and B, as seen in Figure 14 C and D shows that 
there was an increase in lipid droplets from 4G to 11G (blue bars). The highest was in the 
pS-C1 11G 96hrs with lipids condition as expected. This shows us that de novo lipid 
synthesis is very small fraction of total lipid storage. In the 4G condition, KU006794 
caused an increase in lipid droplets, which was unexpected. It caused a decrease in lipid 
droplets in 11G cells with or without lipids which could be due to decreased de novo lipid 
synthesis or decreased uptake of lipids for storage. It is not possible for us to distinguish 
between these two. For the pS-IIg cells, there was no difference in lipid droplets between 
the 11G 96hrs with lipids and 11G 96hrs without lipids conditions. It is possible that pS-
IIg cells had reduced lipid uptake. In the 4G cells, there seem to be no significant 
difference between pS-C1 and pS-IIg cells. In the 11G 96hrs no lipid serum, 
unexpectedly there was similar or increased lipid droplets in the pS-IIg cells in 
comparison to the pS-C1 cells. It seems that the PIP4Kg knockdown did not affect de 
novo lipid synthesis induced by glucose. We acknowledge that the error bars in this 
experiment were large partly due to differences in different fields. To solve that problem, 
we used Celigo to quantify nile red staining on an entire tissue culture well (Figure 14 C 
and D), which confirmed the general trend discussed above. However, we must run more 
experiments to confirm whether these changes were statistically significant. 
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DISCUSSION 
In this study, we investigated the hypothesis that excess glucose increases 
SREBP1 activation through increased TORC1 activity, which leads to de novo lipid 
synthesis and could explain lipid droplet accumulation in INS-1 cells. Through 
immunofluorescence, western blot, qPCR, and nile red staining experiments, we obtained 
data to test if this hypothesis is valid. The three main objectives of this project were the 
following: 1) To test the effect of chronic exposure of INS-1 cells to high glucose 
(11mM) on SREBP activation in comparison to physiological glucose (4mM). 2) To 
determine if KU006794, a TORC1 inhibitor, blocks the SREBP activation in INS-1 cells 
exposed to 11mM glucose. 3) To determine if SREBP activation is affected when PIP4Kg 
(a regulator of TORC1 activity) is suppressed. The results provided evidence that 
SREBP1 is involved in the response of INS-1 cells to excess glucose.  
 
The effect of glucose on proliferation of INS-1 cells 
Although, the results from growth curves provided guidance on how many cells to 
plate for each experiment, they also allowed us to compare the effect of different 
concentrations of glucose on INS-1 proliferation rate. When INS-1 cells were grown in 
4mM or 11mM glucose, they showed an exponential growth phase in both conditions. 
For the cells grown in 4mM glucose, the population grew exponentially for 
approximately 240hrs. For the cells grown in 11mM glucose, the population grew 
exponentially for approximately 120hrs, reached a plateau, and experienced cell death. 
The cells grown in 11mM glucose (excess glucose) grew exponentially for a shorter 
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duration of time than the cells grown in 4mM glucose (physiological/control glucose). 
Despite the fluctuations due to error in plating, we assessed that the doubling time for the 
cells grown in 11mM glucose was approximately 2.5 fold shorter than the doubling time 
for the cells grown in 4mM glucose. This indicates that INS-1 cells proliferate at a faster 
rate in excess glucose.  This supports the concept that there is increased cell growth when 
cells have access to higher amount of nutrients. This was valid also when PIP4Kg was 
knocked down because the pS-IIg cells did not have a different growth pattern in 
comparison to the pS-C1 control cells in both 4mM and 11mM glucose conditions. This 
was seen in both 4mM glucose and 11mM glucose conditions. Therefore, INS-1 cells 
proliferate faster in high glucose.	 
 
Investigative question 1: Does chronic exposure to high glucose (11mM) increase 
SREBP activation in INS-1 cells in comparison to physiological glucose (4mM)? 
 The immunofluorescence experiment allowed us to visualize and measure SREBP 
subcellular localization in INS-1 cells. We hypothesized that nuclear SREBP activity will 
increase when INS-1 cells are exposed to 11mM glucose in comparison to 4mM glucose. 
Therefore, we expected that in the INS-1 cells exposed to 11mM glucose, there would be 
higher SREBP staining within the nucleus (within the Dapi staining) than outside the 
nucleus. The results showed that in 4mM glucose conditions, the cytosolic SREBP 
staining was most prominent which indicated that it was the uncleaved and inactive 
version of SREBP. When the cells were challenged to 11mM glucose, specifically from 
48hrs to 72hrs, the SREBP staining was more prominent in the nucleus. From 48hrs 
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onwards, the ratio of SREBP was higher in the nucleus than the cytosol. This confirmed 
that SREBP is translocated and therefore activated in response to excess glucose (Ikonen, 
2008). The results also showed that nuclear SREBP increased as the exposure time to 
11mM glucose increased. It was highest at 72hrs of exposure to 11mM glucose.  
 
 The western blot experiment allowed us to identify and quantify the short version 
of SREBP, which translocates into the nucleus and a long version of SREBP, which 
remains in the cytosol. According to the immunofluorescence results, we expected that 
the short SREBP would be highest after prolonged exposure to 11mM glucose. This is 
indicated by the calculated ratio of short versus long SREBP. The results showed that 
there was an increase in this ratio under 11mM glucose and there was a linear trend, 
showing that this ratio increased over time. It can be concluded that prolonged exposure 
to high glucose activates SREBP, which translocates to the nucleus to promote the 
transcription of the enzymes involved in de novo lipid synthesis. Quantitative PCR will 
be used in future experiments to confirm this.  
 
Investigative question 2: Does KU006794, a TORC1 inhibitor, block the activation 
of SREBP in INS-1 cells exposed to 11mM glucose? 
 We predicted that KU006794 would decrease SREBP processing and 
translocation into the nucleus, due to TORC1 inhibition. The results of the 
immunofluorescence experiments showed that the cell density was lower with KU006794 
than without. It can be said that this TORC1 inhibitor seems to promote cell death at the 
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concentration used. However, the results of the western blot experiments showed that 
KU006794 did not affect phospho-S6 levels, showing that KU006794 did not affect 
TORC1 activity in the time frame of the experiment. Dr. Rameh’s previous experiments 
have shown that KU006794 is effective at inhibiting TORC1 in a short time frame of 1-
2hrs (Mackey et al., 2014). A previous study showed that effect of rapamycin on SREBP 
activation required at least 12-24hrs of treatment (Duvel et al., 2010). Therefore, our 
experiments required the effect of KU006794 to be effective for at least 24hrs. Our 
results provide little evidence that KU006794 is a long lasting inhibitor probably due to a 
short half-life. In future experiments, another TORC1 inhibitor should be used to allow 
prolonged inhibition of TORC1. In conclusion, the results of KU006794 are inconclusive.  
 
Investigative question 3: Does PIP4Kg suppression affect nuclear SREBP? 
We hypothesized that the PIP4Kg knockdown cells will have a decreased 
activation of SREBP since it was previously shown to regulate TORC1 activity. The data 
showed that PIP4Kg knockdown did not affect SREBP cleavage but it inhibit 
translocation. We can say that PIP4Kg seems to play an important role in SREBP 
translocation to the nucleus in high glucose conditions.  PIP4Kg is a phosphoinositide 
kinase which generates PIP2, a lipid that plays an important role in vesicle trafficking. 
PIP4Kg is present at the Golgi (Mackey et al., 2014). Therefore, it may have a role in 
transporting the short cleaved version of SREBP that is destined to the nucleus. Thus, the 
role of PIP4Kg in SREBP activation could be distinct from its role in TORC1 activation. 
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Lipid Accumulation in INS-1 cells under prolonged exposure to 11mM glucose 
The nile red staining experiments allowed us to visualize and measure the process 
of lipid accumulation in response to excess glucose. The main challenge for this 
experiment was to achieve a high cell density which allows lipid accumulation inside the 
cells. This is because high cell density leads to contact inhibition of proliferation. When 
cells are not proliferating, they can accumulate lipid. As expected, INS-1 cells kept in a 
lipid free serum had lower lipid droplets than cells kept in a lipid rich serum (regardless 
of knocking down PIP4Kg or adding KU006794). It is well known that keeping cells in a 
lipid environment allows for greater lipid accumulation inside the cells. However, this 
also means that we cannot precisely measure de novo lipid synthesis in cells in this 
environment using nile red. Nonetheless, we confirmed that excess glucose increases 
lipid accumulation in cells. Based on the results, we can say that there was very little de 
novo lipid synthesis and more total lipid uptake in the excess glucose conditions. In 
addition, we can conclude that inhibiting TORC1 activity with KU006794 affects lipid 
accumulation in INS-1 cells but knocking down PIP4Kg does not have an effect.  
 
The roles of excess glucose, PIP4Kg, and TORC1 on SREBP activity 
According to the data from the different experiments in this project, we can 
conclude the following (Diagram 3):  
1) Excess glucose stimulates SREBP activity and therefore lipid synthesis in INS-
1 cells.  
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2) SREBP processing and translocation are higher in excess glucose than in 
physiological    
    glucose.  
3) INS-1 cells needed to be challenged with excess glucose for at least 48 hours 
for SREBP activation. 
4) PIP4Kg knockdown inhibited SREBP translocation. 
5) We still do not know if the effect of glucose and PIP4Kg on SREBP is through 
TORC1.  
 
 
 
 
 
 
 
 
 
Diagram 3 - Rationale with results	
We can conclude that maintaining TORC1 activity in INS-1 cells seems to play 
an important role in the process of coping with the challenge of exposure to excess 
glucose. This was seen in how the pS-C1 control cells reacted to excess glucose in the 
different experiments. We can also conclude that PIP4Kg affects SREBP independent of 
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TORC1 activation because knocking down PIP4Kg in INS-1 cells showed significant 
effects on SREBP translocation but not on TORC1 activity. Regarding KU006794, in the 
future, another inhibitor of TORC1 which affects TORC1 activity for a longer time 
should be used.  
 
A study showed that insulin activates SREBP in hepatocytes (Azzout-Marniche et 
al., 2000). INS-1 cells secrete insulin in response to glucose. In future projects, the effect 
of inhibition of insulin secretion on glucose effect of SREBP should be investigated.  
 
The importance of using different methodologies to address SREBP activation in 
this study  
The different methodologies allowed us explore different steps in the process of 
SREBP activation such as translocation, cleavage, and total quantity of SREBP. We 
learnt that SREBP is not an easy transcription factor to measure. The 
immunofluorescence technique provided information on where SREBP is located in cells 
and its translocation from the cytosol to the nucleus. The western blot technique gave 
information on the cleavage of SREBP. One technique was not sufficient to completely 
understand how high glucose activates SREBP for lipid synthesis. We concluded that 
both activation of SREBP and lipid synthesis is enhanced under prolonged exposure to 
excess glucose. It is important to point out that the data of these experiments show an 
association between SREBP activation and increased lipid accumulation but not a causal 
relation.  
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Future directions 
There are some methods that should be used in the future to enhance the validity 
of the results in this study.  Betulin has been recently identified as a molecule that inhibits 
SREBP in liver cells (Tang et al., 2011). Future projects should use betulin to gain a more 
in depth understanding of lipid accumulation and the effect of SREBP activity in 
prolonged exposure to excess glucose. The role of SREBP activation in basal secretion of 
insulin under excess glucose conditions should also be studied. The role of PIP4Kg in 
how it helps SREBP activation should also be further investigated. The total triglyceride 
content in the INS-1 cells should also be measured using special kits available for this 
purpose. Carefully measuring the total triglyceride content will help us understand how 
prolonged exposure to high glucose affects lipid synthesis and how SREBP activation 
allows the lipid accumulation. 
 
The data shown in this thesis project provided further evidence on how excess 
glucose can cause dramatic changes to pancreatic b cells. In the large context in terms of 
the modern lifestyle, the findings allow us to understand how a high carbohydrate diet 
may affect pancreatic b cell metabolism and its functioning. This study indicates that 
SREBP is a potential therapeutic target for diabetes. 
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